19-12-2022, 13:29 CET (Ad hoc press release)
Changes in the Management Board of Eckert & Ziegler
25-11-2022, 15:36 CET (Ad hoc press release)
Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
11-10-2022
Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
04-08-2022
Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
27-07-2022, 12:53 CEST (Ad hoc press release)
Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
21-07-2022
Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
20-07-2022
Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
06-07-2022
Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
05-07-2022, 13:08 CEST (Ad hoc press release)
Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
11-05-2022
Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
08-04-2022
Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR
06-04-2022, 19:52 CEST (Ad hoc press release)
Eckert & Ziegler Publishes Preliminary Figures for Q1/2022 with Deviation in Earnings and Confirms Annual Forecast for 2022
